Loren Ingrid Alving, MD
Neurology · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 38 years
- University of California, San Diego School of Medicine, 1988
Offices
2 locations · Regents of University of California · 4 clinicians in this group
Looking this up.
Hospitals listed: Community Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Alving’s office at (559) 227-4810 to ask if they take your plan before you enroll.
California Medical Board record
Licence G75668 · Current
Licensed to practise in California · since 1992 · expires 2028-09-30 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$29,522
Medicare paid this office $29,522 for 95 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 83 | $19,234 | $140 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 69 | $4,337 | $25 |
| New patient visit (60+ min) | 23 | $3,689 | $160 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 36 | $1,419 | $13 |
Who their Medicare patients are
95 Original Medicare patients in 2024. Average age 77 · Women 55% · Also on Medicaid 13% · Health risk score 1.27. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Dementia 66% · Depression 46% · Diabetes 37% · Coronary heart disease 37% · Chronic kidney disease 28% · Heart failure 19% · Stroke 17% · Atrial fibrillation 16%.
The office billed $72,138, Medicare allowed $38,470 and paid $29,522; for 451 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 95 | 451 | 77 | 1.27 | $72,138 | $29,522 |
| 2023 | 104 | 497 | 76 | 1.33 | $83,861 | $33,199 |
| 2022 | 79 | 157 | 78 | 1.30 | $37,769 | $16,252 |
| 2021 | 61 | 111 | 77 | 1.41 | $26,406 | $11,287 |
| 2020 | 109 | 239 | 76 | 1.40 | $62,325 | $23,614 |
| 2019 | 152 | 256 | 76 | 1.24 | $75,202 | $28,973 |
| 2018 | 132 | 318 | 77 | 1.13 | $92,644 | $32,507 |
| 2017 | 180 | 594 | 76 | 1.31 | $170,279 | $58,514 |
| 2016 | 186 | 691 | 77 | 1.31 | $194,907 | $67,694 |
| 2015 | 180 | 558 | 79 | 1.31 | $157,639 | $57,490 |
| 2014 | 187 | 396 | 79 | 1.18 | $110,591 | $44,373 |
| 2013 | 261 | 403 | 74 | 1.57 | $110,368 | $40,603 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 89 | $19,579 | $138 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 87 | $8,036 | $26 |
| New patient visit (60+ min) | 26 | $4,474 | $172 |
2022: 2 services
| Long return visit (40+ min) | 78 | $14,744 | $135 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | $1,102 | $26 |
2021: 2 services
| Long return visit (40+ min) | 57 | $9,432 | $133 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 12 | $752 | $27 |
2020: 3 services
| Long return visit (40+ min) | 93 | $13,423 | $108 |
| Extended office or other outpatient service, first hour | 50 | $6,736 | $105 |
| Return visit (30+ min) | 23 | $1,787 | $66 |
2019: 3 services
| Long return visit (40+ min) | 102 | $15,922 | $116 |
| New patient visit (60+ min) | 47 | $7,371 | $157 |
| Return visit (30+ min) | 34 | $3,943 | $84 |
2018: 5 services
| Long return visit (40+ min) | 91 | $13,723 | $113 |
| New patient visit (60+ min) | 40 | $6,159 | $154 |
| Neuropsychological testing, interpretation, and report by psychologist or physician per hour | 19 | $5,764 | $77 |
| Return visit (30+ min) | 32 | $3,660 | $83 |
| Extended office or other outpatient service, first hour | 15 | $1,645 | $103 |
2017: 6 services
| Long return visit (40+ min) | 132 | $22,776 | $111 |
| Neuropsychological testing, interpretation, and report by psychologist or physician per hour | 62 | $13,046 | $75 |
| New patient visit (60+ min) | 71 | $11,196 | $158 |
| Return visit (30+ min) | 47 | $5,711 | $82 |
| Neuropsychological testing by technician with interpretation and report by a qualified healthcare professional per hour | 20 | $2,453 | $61 |
| Short return visit (20+ min) | 11 | $635 | $58 |
2016: 6 services
| Long return visit (40+ min) | 127 | $21,959 | $113 |
| Neuropsychological testing, interpretation, and report by psychologist or physician per hour | 63 | $17,448 | $78 |
| New patient visit (60+ min) | 92 | $14,203 | $154 |
| Return visit (30+ min) | 44 | $6,228 | $83 |
| Neuropsychological testing by technician with interpretation and report by a qualified healthcare professional per hour | 30 | $3,976 | $66 |
| Extended office or other outpatient service, first hour | 15 | $1,342 | $79 |
2015: 8 services
| Long return visit (40+ min) | 126 | $22,053 | $116 |
| New patient visit (60+ min) | 81 | $13,212 | $163 |
| Neuropsychological testing, interpretation, and report by psychologist or physician per hour | 44 | $8,494 | $79 |
| Return visit (30+ min) | 49 | $4,850 | $81 |
| Neuropsychological testing by technician with interpretation and report by a qualified healthcare professional per hour | 30 | $3,361 | $67 |
| Exam of neurobehavioral status, first hour | 12 | $2,388 | $75 |
| Psychiatric diagnostic evaluation | 18 | $1,704 | $95 |
| Short return visit (20+ min) | 11 | $635 | $58 |
2014: 7 services
| New patient visit (60+ min) | 109 | $17,823 | $164 |
| Long return visit (40+ min) | 54 | $8,225 | $118 |
| Return visit (30+ min) | 56 | $7,559 | $87 |
| Psychiatric diagnostic evaluation | 42 | $4,515 | $107 |
| Neuropsychological testing, interpretation, and report by psychologist or physician per hour | 22 | $2,046 | $76 |
| Neuropsychological testing by technician with interpretation and report by a qualified healthcare professional per hour | 22 | $2,042 | $68 |
| Short return visit (20+ min) | 23 | $1,492 | $57 |
2013: 5 services
| New patient visit (60+ min) | 90 | $14,024 | $156 |
| Return visit (30+ min) | 66 | $6,964 | $82 |
| Short return visit (20+ min) | 75 | $5,515 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $4,953 | $160 |
| Long return visit (40+ min) | 19 | $2,212 | $111 |
Drugs they prescribed that Part D paid
$5,354
Pharmacies billed $5,354 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 77) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
73 generic and fewer than 11 brand-name prescriptions · $5,354 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Donepezil | 21 | $533 | $25 |
Year by year
| 2024 | 77 | 15 | 0% (0) | None | $5,354 |
| 2023 | 60 | 15 | 0% (0) | 0% | $4,454 |
| 2022 | 66 | 18 | 0% (0) | None | $4,780 |
| 2021 | 62 | 20 | 0% (0) | None | $5,494 |
| 2020 | 123 | 29 | 0% (0) | 13% | $16,822 |
| 2019 | 194 | 43 | 0% (0) | None | $15,196 |
| 2018 | 236 | 39 | 0% (0) | 12% | $33,329 |
| 2017 | 251 | 40 | 0% (0) | 11% | $33,635 |
| 2016 | 277 | 41 | None | 20% | $53,069 |
| 2015 | 355 | 57 | None | 31% | $71,997 |
| 2014 | 534 | 77 | None | 39% | $114,395 |
| 2013 | 709 | 91 | None | 33% | $108,029 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Divalproex | 20 | $1,259 | $63 |
2022: 2 drugs
| Memantine | 12 | $1,084 | $90 |
| Donepezil | 14 | $203 | $15 |
2021: 1 drug
| Escitalopram | 17 | $328 | $19 |
2020: 6 drugs
| Neupro | 13 | $9,304 | $716 |
| Memantine | 21 | $3,341 | $159 |
| Divalproex | 11 | $684 | $62 |
| Donepezil | 13 | $559 | $43 |
| Escitalopram | 20 | $445 | $22 |
| Quetiapine | 14 | $165 | $12 |
2019: 6 drugs
| Memantine | 37 | $3,186 | $86 |
| Memantine Hcl Er | 11 | $2,304 | $209 |
| Divalproex | 43 | $1,698 | $39 |
| Donepezil | 34 | $682 | $20 |
| Escitalopram | 23 | $235 | $10 |
| Quetiapine | 11 | $166 | $15 |
2018: 5 drugs
| Namenda Xr | 15 | $8,349 | $557 |
| Memantine | 58 | $4,360 | $75 |
| Donepezil | 42 | $954 | $23 |
| Divalproex | 17 | $793 | $47 |
| Escitalopram | 16 | $352 | $22 |
2017: 10 drugs
| Namenda Xr | 19 | $13,875 | $730 |
| Rivastigmine | 13 | $4,152 | $319 |
| Memantine | 34 | $2,549 | $75 |
| Donepezil | 53 | $1,347 | $25 |
| Divalproex | 24 | $503 | $21 |
| Carbidopa-Levodopa | 11 | $499 | $45 |
| Levetiracetam | 14 | $301 | $22 |
| Atorvastatin | 13 | $140 | $11 |
| Venlafaxine Hcl Er | 14 | $92 | $7 |
| Escitalopram | 11 | $74 | $7 |
2016: 9 drugs
| Namenda Xr | 37 | $24,316 | $657 |
| Rivastigmine | 14 | $4,344 | $310 |
| Memantine | 29 | $3,072 | $106 |
| Donepezil | 46 | $769 | $17 |
| Divalproex | 31 | $537 | $17 |
| Quetiapine | 21 | $395 | $19 |
| Carbidopa-Levodopa | 15 | $310 | $21 |
| Levetiracetam | 14 | $187 | $13 |
| Atorvastatin | 13 | $174 | $13 |
2015: 9 drugs
| Namenda Xr | 50 | $25,574 | $511 |
| Namenda | 37 | $19,145 | $517 |
| Exelon | 14 | $12,076 | $863 |
| Memantine | 18 | $2,798 | $155 |
| Donepezil | 97 | $1,496 | $15 |
| Mirtazapine | 20 | $408 | $20 |
| Divalproex | 21 | $390 | $19 |
| Quetiapine | 29 | $358 | $12 |
| Amitriptyline | 12 | $102 | $8 |
2014: 10 drugs
| Namenda | 113 | $55,505 | $491 |
| Namenda Xr | 64 | $29,809 | $466 |
| Azilect | 12 | $5,894 | $491 |
| Donepezil | 111 | $1,991 | $18 |
| Quetiapine | 60 | $1,340 | $22 |
| Levetiracetam | 25 | $1,326 | $53 |
| Carbidopa-Levodopa | 23 | $656 | $29 |
| Divalproex | 24 | $255 | $11 |
| Mirtazapine | 15 | $237 | $16 |
| Clonazepam | 17 | $92 | $5 |
2013: 17 drugs
| Namenda | 167 | $56,432 | $338 |
| Vimpat | 18 | $13,604 | $756 |
| Exelon | 21 | $7,090 | $338 |
| Azilect | 12 | $5,189 | $432 |
| Carbidopa-Levodopa Er | 21 | $2,411 | $115 |
| Escitalopram | 24 | $2,173 | $91 |
| Donepezil | 96 | $1,938 | $20 |
| Quetiapine | 50 | $1,806 | $36 |
| Levetiracetam | 37 | $1,715 | $46 |
| Carbidopa-Levodopa | 47 | $1,506 | $32 |
| Gabapentin | 34 | $1,385 | $41 |
| Ropinirole | 11 | $486 | $44 |
| Phenytoin Sodium Extended | 18 | $229 | $13 |
| Glycopyrrolate | 12 | $181 | $15 |
| Amantadine | 12 | $153 | $13 |
| Clonazepam | 20 | $114 | $6 |
| Amitriptyline | 22 | $71 | $3 |
Professional record
- NPI
- 1861423501
- Licence
- CA G75668California G75668: Current · expires 2028-09-30
- Trained
- University of California, San Diego School of Medicine, 1988 · 38 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X); Federal specialty code 2084B0040X (2084B0040X)
- Mailing address
- 6137 N Thesta St, Suite 101b, Fresno, CA, 93710
- NPI first listed
- 2006-07-05
- NPI last updated
- 2015-11-19
This is when the NPI record was last certified, not a medical board exam.